These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

872 related articles for article (PubMed ID: 26018115)

  • 21. Infectious risk of add-on leflunomide or tacrolimus versus TNF inhibitors among patients with rheumatoid arthritis receiving background methotrexate: A population-based cohort study.
    Shin A; Lee JH; Ha YJ; Lee YJ; Lee EB; Kang EH
    Semin Arthritis Rheum; 2022 Aug; 55():152019. PubMed ID: 35567808
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study.
    Kim SC; Solomon DH; Rogers JR; Gale S; Klearman M; Sarsour K; Schneeweiss S
    Arthritis Rheumatol; 2017 Jun; 69(6):1154-1164. PubMed ID: 28245350
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: a case-control study in Asia.
    Liao TL; Chen YM; Liu HJ; Chen DY
    BMJ Open; 2017 Jan; 7(1):e014032. PubMed ID: 28057661
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV Disease.
    Jin Y; Kang EH; Brill G; Desai RJ; Kim SC
    J Rheumatol; 2018 Aug; 45(9):1240-1248. PubMed ID: 29764964
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of Tumor Necrosis Factor Inhibitors in Combination with Various csDMARD in the Treatment of Rheumatoid Arthritis: Data from the DREAM Registry.
    Manders SH; Kievit W; Jansen TL; Stolk JN; Visser H; Schilder AM; Vonkeman HE; Adang E; van de Laar MA; van Riel PL
    J Rheumatol; 2016 Oct; 43(10):1787-1794. PubMed ID: 27481900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative Persistence of Methotrexate and Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    George MD; Baker JF; Ogdie A
    J Rheumatol; 2020 Jun; 47(6):826-834. PubMed ID: 31474599
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative risk of infections between JAK inhibitors versus TNF inhibitors among patients with rheumatoid arthritis: a cohort study.
    Choi SR; Shin A; Ha YJ; Lee YJ; Lee EB; Kang EH
    Arthritis Res Ther; 2023 Jul; 25(1):129. PubMed ID: 37495973
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy.
    Winthrop KL; Curtis JR; Lindsey S; Tanaka Y; Yamaoka K; Valdez H; Hirose T; Nduaka CI; Wang L; Mendelsohn AM; Fan H; Chen C; Bananis E
    Arthritis Rheumatol; 2017 Oct; 69(10):1960-1968. PubMed ID: 28845604
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retrospective analysis to describe associations between tumor necrosis factor alpha inhibitors and COPD-related hospitalizations.
    Accortt NA; Chung JB; Bonafede M; Limone BL; Mannino DM
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2085-2094. PubMed ID: 28790811
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study.
    Buchbinder R; Van Doornum S; Staples M; Lassere M; March L
    BMC Musculoskelet Disord; 2015 Oct; 16():309. PubMed ID: 26481039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of tuberculosis in rheumatoid arthritis patients on tumour necrosis factor-alpha inhibitor treatment in Taiwan.
    Ke WM; Chen LS; Parng IM; Chen WW; On AW
    Int J Tuberc Lung Dis; 2013 Dec; 17(12):1590-5. PubMed ID: 24200274
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor necrosis factor-α inhibitor treatment and the risk of incident cardiovascular events in patients with early rheumatoid arthritis: a nested case-control study.
    Desai RJ; Rao JK; Hansen RA; Fang G; Maciejewski M; Farley J
    J Rheumatol; 2014 Nov; 41(11):2129-36. PubMed ID: 25086079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors.
    Martínez-Feito A; Plasencia-Rodríguez C; Navarro-Compán V; Hernández-Breijo B; González MÁ; Monjo I; Nuño L; Nozal P; Pascual-Salcedo D; Balsa A
    Clin Rheumatol; 2019 Mar; 38(3):949-954. PubMed ID: 30402698
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Retention of the second-line biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis failing one tumor necrosis factor alpha inhibitor: data from the BioRx.si registry.
    Rotar Z; Hočevar A; Rebolj Kodre A; Praprotnik S; Tomšič M;
    Clin Rheumatol; 2015 Oct; 34(10):1787-93. PubMed ID: 26345633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment strategies in patients with rheumatoid arthritis for whom methotrexate monotherapy has failed: data from the NOR-DMARD register.
    Lie E; van der Heijde D; Uhlig T; Mikkelsen K; Kalstad S; Kaufmann C; Rødevand E; Kvien TK
    Ann Rheum Dis; 2011 Dec; 70(12):2103-10. PubMed ID: 21875874
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk for Herpes Zoster in Tofacitinib-Treated Rheumatoid Arthritis Patients With and Without Concomitant Methotrexate and Glucocorticoids.
    Curtis JR; Xie F; Yang S; Bernatsky S; Chen L; Yun H; Winthrop K
    Arthritis Care Res (Hoboken); 2019 Sep; 71(9):1249-1254. PubMed ID: 30295428
    [TBL] [Abstract][Full Text] [Related]  

  • 37. One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry.
    Harrold LR; Litman HJ; Saunders KC; Dandreo KJ; Gershenson B; Greenberg JD; Low R; Stark J; Suruki R; Jaganathan S; Kremer JM; Yassine M
    Arthritis Res Ther; 2018 Jan; 20(1):2. PubMed ID: 29329557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration.
    Lauper K; Nordström DC; Pavelka K; Hernández MV; Kvien TK; Kristianslund EK; Santos MJ; Rotar Ž; Iannone F; Codreanu C; Lukina G; Gale SL; Sarsour K; Luder Y; Courvoisier DS; Gabay C
    Ann Rheum Dis; 2018 Sep; 77(9):1276-1282. PubMed ID: 29730637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative risk of osteoporotic fracture among patients with rheumatoid arthritis receiving TNF inhibitors versus other biologics: a cohort study.
    Shin A; Park EH; Dong YH; Ha YJ; Lee YJ; Lee EB; Song YW; Kang EH
    Osteoporos Int; 2020 Nov; 31(11):2131-2139. PubMed ID: 32514765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased risk of herpes zoster with tofacitinib treatment in Korean patients with rheumatoid arthritis: a single-center prospective study.
    Song YJ; Cho SK; Kim H; Kim HW; Nam E; Jeon JY; Yoo HJ; Choi CB; Kim TH; Jun JB; Bae SC; Yoo DH; Sung YK
    Sci Rep; 2023 May; 13(1):7877. PubMed ID: 37188765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.